-- Sigma-Aldrich's supply chain and eCommerce strength will
allow broader availability and accessibility of products to
customers
PLEASANTON, California,
March 19, 2015 /PRNewswire/ -- Roche
(SIX: RO, ROG; OTCQX: RHHBY) announced today a global distribution
agreement for its Biochemical Reagents product portfolio with
Sigma-Aldrich Corporation (NASDAQ: SIAL). These products include
kits and enzymes for cellular analysis, proteomics and conventional
PCR applications. Under the terms of the agreement, Sigma-Aldrich
will acquire exclusive rights for worldwide distribution of these
products. Roche remains the legal manufacturer of the products.
"With this agreement, we are able to provide more customers with
access to high-quality Roche Biochemical Reagents products through
Sigma-Aldrich's expanded eCommerce and distribution networks," said
Paul Brown, Head of Roche Molecular
Diagnostics. "In addition, this will allow us the flexibility to
devote more resources in our focus areas."
"Sigma-Aldrich is excited to offer the global scientific
community access to Roche's leading portfolio of scientific tools
and reagents. The addition of these life science tools supports our
strategy to augment our portfolio with products that accelerate
customer scientific research programs," said Eric Green, Executive Vice President and
President, Sigma-Aldrich Research. "We look forward to working with
Roche in this relationship."
Transition of the Roche portfolio to Sigma-Aldrich is expected
to take place in 2015. In the interim, these products will continue
to be available through existing Roche channels. For more
information, visit www.lifescience.roche.com or
www.sigma-aldrich.com.
About Sigma-Aldrich
Sigma-Aldrich, a leading Life Science and Technology company
focused on enhancing human health and safety, manufactures and
distributes 250,000 chemicals, biochemicals and other essential
products to more than 1.4 million customers globally in research
and applied labs as well as in industrial and commercial markets.
With three distinct business units - Research, Applied and SAFC
Commercial - Sigma-Aldrich is committed to enabling science to
improve the quality of life. The Company operates in 37 countries,
has approximately 9,300 employees worldwide and had sales of
$2.79 billion in 2014. For more
information about Sigma-Aldrich, please visit its website at
www.sigma-aldrich.com.
About Roche
Headquartered in Basel,
Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and
diagnostics. Roche is the world's largest biotech company, with
truly differentiated medicines in oncology, immunology, infectious
diseases, ophthalmology and neuroscience. Roche is also the world
leader in in vitro diagnostics and tissue-based cancer diagnostics,
and a frontrunner in diabetes management. Roche's personalised
healthcare strategy aims at providing medicines and diagnostics
that enable tangible improvements in the health, quality of life
and survival of patients. Founded in 1896, Roche has been making
important contributions to global health for more than a century.
Twenty-four medicines developed by Roche are included in the World
Health Organization Model Lists of Essential Medicines, among them
life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide,
invested 8.9 billion Swiss francs in
R&D and posted sales of 47.5 billion
Swiss francs. Genentech, in the
United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical,
Japan. For more information,
please visit roche.com.
All trademarks used or mentioned in this release are protected
by law.
For media inquiries please contact:
Bob Purcell, Roche Molecular
Diagnostics
888-545-2443
Claudia Panozzo, Austria
+43 1 277 87 360
Silvia Zucca, Italy
+39 039 2817 612
Francisco Aguilar-Alvarez,
Spain
+34 93583 4011
Eudes de Villiers, France
+33 4 76 76 31 26
Banu Kutlu, Turkey
00902123060606
Harald Borrmann, Switzerland
+41 41 799 6253
Kate Hoile, UK
+44 1444 256591
Jan Schreiber, Germany
+49 621 759 5156
